Developer docs
API playgroundTry for free, no card

Search company profiles

CREATE Medicines

Full company profile

uuid0000555

Namestring
CREATE Medicines
Legal namestring
CREATE Medicines, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

CREATE Medicines is a clinical-stage biotechnology company pioneering in vivo CAR therapies through a proprietary mRNA-lipid nanoparticle (mRNA-LNP) platform that programs immune cells directly inside the body, eliminating the need for ex vivo cell harvesting or lymphodepletion conditioning. Founded in 2019 and headquartered at 300 Technology Square in Cambridge, Massachusetts, the company was previously known as Myeloid Therapeutics before rebranding in fall 2025 to reflect the platform's expanded scope across T cells, NK cells, and myeloid cells and its entry into autoimmune disease alongside oncology. The company maintains 11–50 employees and has dosed more than 50 patients across its clinical programs, which represents the largest clinical dataset in the in vivo CAR field.

The core technology stack comprises three differentiated layers: a redosable mRNA-LNP delivery system, a multi-immune CAR architecture that programs T, NK, and myeloid cells simultaneously, and the RetroT platform — an all-RNA genome integration system using human LINE-1 retrotransposon machinery to enable site-specific genetic payload insertion without viral vectors or double-strand breaks. The pipeline includes four clinical-stage oncology assets (MT-302 targeting TROP2 in frontline gastroesophageal cancer, MT-303 targeting GPC3 in frontline hepatocellular carcinoma, MT-304 targeting HER2 across multiple solid tumors, and CRT-401 targeting HER2 x TROP2) and two preclinical autoimmune assets (CRT-402 targeting CD19 and CRT-403 targeting CD19 x BCMA via the RetroT platform).

CREATE Medicines is pre-revenue and generates no product sales, with future revenue expected to flow through pharmaceutical product sales and partnership/licensing transactions contingent on regulatory approval. Go-to-market activity is conducted through clinical collaborations (most prominently with Amsterdam University Medical Center for MT-302 in frontline GEJ), business development outreach via partnering@createmedicines.com, and presence at major industry venues including J.P. Morgan Healthcare Conference, AACR, SITC, and Keystone Symposia. The company is venture-backed by Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners, and Alexandria Venture Investments, and led by founder and CEO Daniel Getts, Executive Chairman Ron Philip, and a senior team recruited from IDEAYA, Bristol Myers Squibb, Vertex, TCR2, EMD Serono, and Spark Therapeutics.

Short descriptiontext

CREATE Medicines is a clinical-stage biotechnology company pioneering in vivo CAR therapies through proprietary mRNA-LNP immune cell programming, directly engineering T cells, NK cells, and myeloid cells inside the body to treat oncology and autoimmune disease patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vivo CAR therapy, mRNA-LNP immunotherapy, CAR-T cell therapy, oncology therapeutics, autoimmune disease therapy
Industry3 codes
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
In Vivo CAR Immunotherapy
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Product Sales
TypeOne Time License
Description

As a clinical-stage biotechnology company, CREATE Medicines does not yet have commercial products. The company is developing in vivo CAR therapies for oncology and autoimmune diseases. If products receive regulatory approval, revenue would be generated through pharmaceutical product sales.

createmedicines.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CREATE Medicines is a clinical-stage biotechnology company developing in vivo CAR (chimeric antigen receptor) therapies that program immune cells directly inside the body using its proprietary mRNA-Lipid Nanoparticle (mRNA-LNP) platform. Its pipeline spans solid tumor oncology programs (MT-302 for TROP2-positive gastroesophageal cancer, MT-303 for GPC3 hepatocellular carcinoma, MT-304 for HER2-positive solid tumors, CRT-401 for HER2 x TROP2) and B cell-driven autoimmune disease programs (CRT-402 for CD19, CRT-403 for CD19 x BCMA). The RetroT platform provides all-RNA genome integration for durable gene engineering without viral vectors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Complete B cell depletion demonstrated in non-human primates with proprietary in vivo CAR-T platform
+3 more records
Product overview1 text field

CREATE Medicines is a clinical-stage biotechnology company pioneering an in vivo immune programming platform based on proprietary mRNA-LNP CAR technology. The platform enables direct programming of T cells, NK cells, and myeloid cells inside the body, producing scalable, repeat-dose, off-the-shelf immunotherapies. The company operates a multi-product portfolio spanning oncology and autoimmune disease: clinical-stage programs include MT-302 (TROP2-targeted for gastroesophageal cancer), MT-303 (GPC3-targeted for hepatocellular carcinoma), MT-304 (HER2-targeted multi-immune therapy for breast/gastric cancers), and CRT-401 (HER2 x TROP2 multi-immune CAR). Preclinical programs include CRT-402 (CD19 CAR-T for autoimmune disease) and CRT-403 (dual CD19 x BCMA CAR for autoimmune disease using RetroT technology). The RetroT platform is an all-RNA genome integration system using LINE-1 retrotransposon machinery for stable gene delivery without viral vectors.

Product and service8 records
1MT-302
CategoryClinical-stage in vivo CAR therapy
Description

In vivo CAR therapy targeting TROP2 for frontline gastroesophageal junction (GEJ) cancer. Programs myeloid cells using CREATE's redosable mRNA-LNP system. Demonstrated proof-of-mechanism and early anti-tumor activity in first-in-human studies.

2MT-303
CategoryClinical-stage in vivo CAR therapy
Description

In vivo GPC3-targeted CAR therapy for first-line metastatic hepatocellular carcinoma (HCC). Evaluated in combination with standard immunotherapies to achieve deeper, durable responses.

3MT-304
CategoryClinical-stage in vivo CAR therapy
Description

First-in-class multi-immune in vivo HER2-targeted CAR therapy that simultaneously programs NK and myeloid cells using CREATE's mRNA-LNP platform. Designed for HER2-positive breast cancer and other HER2-positive solid tumors including gastric cancer.

4CRT-401
CategoryClinical-stage in vivo CAR therapy
Description

Multi-immune in vivo CAR therapy targeting both HER2 and TROP2 antigens, simultaneously programming T cells, NK cells, and myeloid cells using the proprietary mRNA-LNP platform.

5CRT-402
CategoryPreclinical in vivo CAR-T therapy
Description

CD19-targeted in vivo CAR-T therapy for autoimmune disease. Demonstrated deep and durable B cell depletion in non-human primates, with potential for immune reset through repeat dosing flexibility. Advancing toward clinical entry for B cell-driven autoimmune indications.

6CRT-403
CategoryPreclinical in vivo CAR therapy
Description

Dual CAR CD19 x BCMA directed therapy utilizing the RetroT platform, designed to broaden therapeutic reach across refractory autoimmune indications.

7RetroT Platform
CategoryTechnology platform
Description

All-RNA genome integration platform using human LINE-1 retrotransposon machinery for site-specific genetic payload insertion without DNA double-strand breaks or viral vectors. Enables stable, durable cell engineering in vivo as the foundation for durable CAR expression in pipeline assets such as CRT-403.

8mRNA-LNP CAR Platform
CategoryTechnology platform
Description

Proprietary mRNA-lipid nanoparticle (LNP) platform that enables direct programming of T cells, NK cells, and myeloid cells within the body. Supports repeatable dosing without lymphodepletion or ex vivo manufacturing, and underpins all of CREATE's in vivo CAR clinical and preclinical programs.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Clinical collaboration where Amsterdam UMC dosed the first patient in a clinical trial evaluating CREATE's MT-302 in vivo CAR therapy combined with standard front-line treatments for advanced gastroesophageal cancer. The trial assesses safety, tolerability, and preliminary efficacy, marking a significant step toward scalable, off-the-shelf cell therapies for solid tumors.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Capstan is a direct peer pursuing in vivo CAR-T cell engineering using mRNA-LNP delivery to reprogram immune cells inside the body. Both companies target the same core thesis: replacing ex vivo CAR-T manufacturing with in vivo programming for oncology and autoimmune indications.

TypeDirect peer
Description

Umoja is developing in vivo CAR-T cell therapies using a proprietary platform to generate CAR-T cells in vivo, directly comparable to CREATE's mRNA-LNP approach. Both target oncology and autoimmune indications with off-the-shelf, repeat-dose potential.

TypeDirect peer
Description

Cartesian is a clinical-stage developer of RNA cell therapy engineering, including mRNA-based CAR-T approaches. Its Descartes-08 program (anti-BCMA) targets autoimmune disease with similar mechanism to CREATE's CRT-402/CRT-403 CD19/BCMA programs.

TypeBroad incumbent
Description

Allogene is a leading allogeneic CAR-T developer with broader portfolio across hematologic malignancies and solid tumors. While focused on ex vivo manufacturing rather than in vivo, it is a major competitive incumbent shaping the cell therapy landscape CREATE is targeting.

TypeBroad incumbent
Description

Caribou develops allogeneic CAR-T cell therapies using CRISPR gene editing, with clinical programs in hematologic malignancies. It represents a broader CAR-T incumbent focused on next-generation engineered cell therapy approaches.

TypeBroad incumbent
Description

CRISPR Therapeutics is a leading gene-editing biotech with Casgevy (the first approved CRISPR therapy) and a broader pipeline including CAR-T programs. It is a broad incumbent in the engineered cell therapy space relevant to CREATE's in vivo CAR approach.

TypeBroad incumbent
Description

Intellia is a clinical-stage gene editing company developing in vivo CRISPR/Cas9 therapies. While primarily focused on gene editing rather than CAR delivery, it is broadly comparable as an in vivo genetic medicine platform targeting similar patient populations.

TypeEmerging player
Description

Beam is a clinical-stage developer of base editing therapies for hematologic and other diseases. As a next-generation genetic medicine platform, it represents an emerging alternative approach to cell engineering with partial overlap in target indications.

TypeEmerging player
Description

Precision Bio develops allogeneic CAR-T therapies using its proprietary ARCUS gene editing platform. Its focus on off-the-shelf cell therapies for oncology and autoimmune diseases provides partial overlap with CREATE's in vivo CAR strategy.

TypeOthers
Description

Moderna is the leading mRNA-LNP platform company with extensive delivery technology expertise. While primarily focused on vaccines and protein replacement rather than in vivo CAR, it is a key ecosystem participant and potential partner/licensor in the mRNA-LNP space underpinning CREATE's platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CREATE Medicines

In Vivo CAR Immunotherapycreatemedicines.com

CREATE Medicines is a clinical-stage biotechnology company pioneering in vivo CAR therapies through proprietary mRNA-LNP immune cell programming, directly engineering T cells, NK cells, and myeloid cells inside the body to treat oncology and autoimmune disease patients.

What CREATE Medicines does

CREATE Medicines is a clinical-stage biotechnology company pioneering in vivo CAR therapies through a proprietary mRNA-lipid nanoparticle (mRNA-LNP) platform that programs immune cells directly inside the body, eliminating the need for ex vivo cell harvesting or lymphodepletion conditioning. Founded in 2019 and headquartered at 300 Technology Square in Cambridge, Massachusetts, the company was previously known as Myeloid Therapeutics before rebranding in fall 2025 to reflect the platform's expanded scope across T cells, NK cells, and myeloid cells and its entry into autoimmune disease alongside oncology. The company maintains 11–50 employees and has dosed more than 50 patients across its clinical programs, which represents the largest clinical dataset in the in vivo CAR field.

The core technology stack comprises three differentiated layers: a redosable mRNA-LNP delivery system, a multi-immune CAR architecture that programs T, NK, and myeloid cells simultaneously, and the RetroT platform — an all-RNA genome integration system using human LINE-1 retrotransposon machinery to enable site-specific genetic payload insertion without viral vectors or double-strand breaks. The pipeline includes four clinical-stage oncology assets (MT-302 targeting TROP2 in frontline gastroesophageal cancer, MT-303 targeting GPC3 in frontline hepatocellular carcinoma, MT-304 targeting HER2 across multiple solid tumors, and CRT-401 targeting HER2 x TROP2) and two preclinical autoimmune assets (CRT-402 targeting CD19 and CRT-403 targeting CD19 x BCMA via the RetroT platform).

CREATE Medicines is pre-revenue and generates no product sales, with future revenue expected to flow through pharmaceutical product sales and partnership/licensing transactions contingent on regulatory approval. Go-to-market activity is conducted through clinical collaborations (most prominently with Amsterdam University Medical Center for MT-302 in frontline GEJ), business development outreach via partnering@createmedicines.com, and presence at major industry venues including J.P. Morgan Healthcare Conference, AACR, SITC, and Keystone Symposia. The company is venture-backed by Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners, and Alexandria Venture Investments, and led by founder and CEO Daniel Getts, Executive Chairman Ron Philip, and a senior team recruited from IDEAYA, Bristol Myers Squibb, Vertex, TCR2, EMD Serono, and Spark Therapeutics.

CREATE Medicines firmographics

Firmographics
Name
CREATE Medicines
Legal name
CREATE Medicines, Inc.
Website
https://createmedicines.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
CREATE Medicines is a clinical-stage biotechnology company pioneering in vivo CAR therapies through proprietary mRNA-LNP immune cell programming, directly engineering T cells, NK cells, and myeloid cells inside the body to treat oncology and autoimmune disease patients.
Ownership category
akta.pro rank

CREATE Medicines industry classification

Industry
Product category
In Vivo CAR Immunotherapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • In vivo CAR therapy
  • MRNA-LNP immunotherapy
  • CAR-T cell therapy
  • Oncology therapeutics
  • Autoimmune disease therapy

Where CREATE Medicines is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CREATE Medicines business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Therapeutic Product Sales: As a clinical-stage biotechnology company, CREATE Medicines does not yet have commercial products. The company is developing in vivo CAR therapies for oncology and autoimmune diseases. If products receive regulatory approval, revenue would be generated through pharmaceutical product sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

CREATE Medicines product offering

Product offering

Core offering

CREATE Medicines is a clinical-stage biotechnology company developing in vivo CAR (chimeric antigen receptor) therapies that program immune cells directly inside the body using its proprietary mRNA-Lipid Nanoparticle (mRNA-LNP) platform. Its pipeline spans solid tumor oncology programs (MT-302 for TROP2-positive gastroesophageal cancer, MT-303 for GPC3 hepatocellular carcinoma, MT-304 for HER2-positive solid tumors, CRT-401 for HER2 x TROP2) and B cell-driven autoimmune disease programs (CRT-402 for CD19, CRT-403 for CD19 x BCMA). The RetroT platform provides all-RNA genome integration for durable gene engineering without viral vectors.

Product overview

CREATE Medicines is a clinical-stage biotechnology company pioneering an in vivo immune programming platform based on proprietary mRNA-LNP CAR technology. The platform enables direct programming of T cells, NK cells, and myeloid cells inside the body, producing scalable, repeat-dose, off-the-shelf immunotherapies. The company operates a multi-product portfolio spanning oncology and autoimmune disease: clinical-stage programs include MT-302 (TROP2-targeted for gastroesophageal cancer), MT-303 (GPC3-targeted for hepatocellular carcinoma), MT-304 (HER2-targeted multi-immune therapy for breast/gastric cancers), and CRT-401 (HER2 x TROP2 multi-immune CAR). Preclinical programs include CRT-402 (CD19 CAR-T for autoimmune disease) and CRT-403 (dual CD19 x BCMA CAR for autoimmune disease using RetroT technology). The RetroT platform is an all-RNA genome integration system using LINE-1 retrotransposon machinery for stable gene delivery without viral vectors.

Differentiator

Problem solved

Functional benefit

Products and services

  • MT-302 In vivo CAR therapy targeting TROP2 for frontline gastroesophageal junction (GEJ) cancer. Programs myeloid cells using CREATE's redosable mRNA-LNP system. Demonstrated proof-of-mechanism and early anti-tumor activity in first-in-human studies.
  • MT-303 In vivo GPC3-targeted CAR therapy for first-line metastatic hepatocellular carcinoma (HCC). Evaluated in combination with standard immunotherapies to achieve deeper, durable responses.
  • MT-304 First-in-class multi-immune in vivo HER2-targeted CAR therapy that simultaneously programs NK and myeloid cells using CREATE's mRNA-LNP platform. Designed for HER2-positive breast cancer and other HER2-positive solid tumors including gastric cancer.
  • CRT-401 Multi-immune in vivo CAR therapy targeting both HER2 and TROP2 antigens, simultaneously programming T cells, NK cells, and myeloid cells using the proprietary mRNA-LNP platform.
  • CRT-402 CD19-targeted in vivo CAR-T therapy for autoimmune disease. Demonstrated deep and durable B cell depletion in non-human primates, with potential for immune reset through repeat dosing flexibility. Advancing toward clinical entry for B cell-driven autoimmune indications.
  • CRT-403 Dual CAR CD19 x BCMA directed therapy utilizing the RetroT platform, designed to broaden therapeutic reach across refractory autoimmune indications.
  • RetroT Platform All-RNA genome integration platform using human LINE-1 retrotransposon machinery for site-specific genetic payload insertion without DNA double-strand breaks or viral vectors. Enables stable, durable cell engineering in vivo as the foundation for durable CAR expression in pipeline assets such as CRT-403.
  • mRNA-LNP CAR Platform Proprietary mRNA-lipid nanoparticle (LNP) platform that enables direct programming of T cells, NK cells, and myeloid cells within the body. Supports repeatable dosing without lymphodepletion or ex vivo manufacturing, and underpins all of CREATE's in vivo CAR clinical and preclinical programs.

Quantifiable outcome

  • Complete B cell depletion demonstrated in non-human primates with proprietary in vivo CAR-T platform
  • +3 more outcomes

Companies that use CREATE Medicines

Customer profile

Segments3 records

Ideal customer profiles2 records

CREATE Medicines technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

CREATE Medicines partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Amsterdam University Medical CentercoreStrategic or Co-development Partner · 1 October 2025Clinical collaboration where Amsterdam UMC dosed the first patient in a clinical trial evaluating CREATE's MT-302 in vivo CAR therapy combined with standard front-line treatments for advanced gastroesophageal cancer. The trial assesses safety, tolerability, and preliminary efficacy, marking a significant step toward scalable, off-the-shelf cell therapies for solid tumors.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

CREATE Medicines competitors and assessment

Company assessment

Direct peers

  • Capstan Therapeutics: Capstan is a direct peer pursuing in vivo CAR-T cell engineering using mRNA-LNP delivery to reprogram immune cells inside the body. Both companies target the same core thesis: replacing ex vivo CAR-T manufacturing with in vivo programming for oncology and autoimmune indications.
  • Umoja Biopharma: Umoja is developing in vivo CAR-T cell therapies using a proprietary platform to generate CAR-T cells in vivo, directly comparable to CREATE's mRNA-LNP approach. Both target oncology and autoimmune indications with off-the-shelf, repeat-dose potential.
  • Cartesian Therapeutics: Cartesian is a clinical-stage developer of RNA cell therapy engineering, including mRNA-based CAR-T approaches. Its Descartes-08 program (anti-BCMA) targets autoimmune disease with similar mechanism to CREATE's CRT-402/CRT-403 CD19/BCMA programs.

Broad incumbents

  • Allogene Therapeutics: Allogene is a leading allogeneic CAR-T developer with broader portfolio across hematologic malignancies and solid tumors. While focused on ex vivo manufacturing rather than in vivo, it is a major competitive incumbent shaping the cell therapy landscape CREATE is targeting.
  • Caribou Biosciences: Caribou develops allogeneic CAR-T cell therapies using CRISPR gene editing, with clinical programs in hematologic malignancies. It represents a broader CAR-T incumbent focused on next-generation engineered cell therapy approaches.
  • CRISPR Therapeutics: CRISPR Therapeutics is a leading gene-editing biotech with Casgevy (the first approved CRISPR therapy) and a broader pipeline including CAR-T programs. It is a broad incumbent in the engineered cell therapy space relevant to CREATE's in vivo CAR approach.
  • Intellia Therapeutics: Intellia is a clinical-stage gene editing company developing in vivo CRISPR/Cas9 therapies. While primarily focused on gene editing rather than CAR delivery, it is broadly comparable as an in vivo genetic medicine platform targeting similar patient populations.

Emerging players

  • Beam Therapeutics: Beam is a clinical-stage developer of base editing therapies for hematologic and other diseases. As a next-generation genetic medicine platform, it represents an emerging alternative approach to cell engineering with partial overlap in target indications.
  • Precision Biosciences: Precision Bio develops allogeneic CAR-T therapies using its proprietary ARCUS gene editing platform. Its focus on off-the-shelf cell therapies for oncology and autoimmune diseases provides partial overlap with CREATE's in vivo CAR strategy.

Others

  • Moderna: Moderna is the leading mRNA-LNP platform company with extensive delivery technology expertise. While primarily focused on vaccines and protein replacement rather than in vivo CAR, it is a key ecosystem participant and potential partner/licensor in the mRNA-LNP space underpinning CREATE's platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

CREATE Medicines social profiles

Digital presence

CREATE Medicines financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CREATE Medicines leadership team

Management profile

Number of profiles

Profiles12 records

CREATE Medicines funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CREATE Medicines M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CREATE Medicines

What does CREATE Medicines do?

CREATE Medicines is a clinical-stage biotechnology company developing in vivo CAR (chimeric antigen receptor) therapies that program immune cells directly inside the body using its proprietary mRNA-Lipid Nanoparticle (mRNA-LNP) platform. Its pipeline spans solid tumor oncology programs (MT-302 for TROP2-positive gastroesophageal cancer, MT-303 for GPC3 hepatocellular carcinoma, MT-304 for HER2-positive solid tumors, CRT-401 for HER2 x TROP2) and B cell-driven autoimmune disease programs (CRT-402 for CD19, CRT-403 for CD19 x BCMA). The RetroT platform provides all-RNA genome integration for durable gene engineering without viral vectors.

Is CREATE Medicines a public or private company?

CREATE Medicines is a private company. It is classified as venture growth investor backed and is currently operating.

When was CREATE Medicines founded?

CREATE Medicines was founded in 2019. It employs 11 to 50 people.

Where is CREATE Medicines based?

CREATE Medicines is headquartered in Cambridge, United States, in the North America region.

How does CREATE Medicines make money?

One revenue line is on record: therapeutic Product Sales.

Who are CREATE Medicines's main competitors?

Direct peers on record are Capstan Therapeutics, Umoja Biopharma and Cartesian Therapeutics. Broad incumbents are Allogene Therapeutics, Caribou Biosciences, CRISPR Therapeutics and Intellia Therapeutics. Emerging players are Beam Therapeutics and Precision Biosciences. Moderna is listed as an others.

Does CREATE Medicines have an API?

No public API is recorded for CREATE Medicines.

What industry is CREATE Medicines in?

CREATE Medicines's product category is In Vivo CAR Immunotherapy. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCREATE Medicines to Host Investor and Partnering Meetings at the 2026 Jefferies Global Healthcare Conference in LondonCREATE Medicines' CEO and CMO will host investor and partner meetings at the Jefferies Global Healthcare Conference in London, Nov 16-19, 2026. The company has over 80 patients treated in its in vivo CAR programs, including CRT-402, MT-303, MT-302, and MT-304.MorningstarCREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGeneCREATE Medicines announced a strategic collaboration with WestGene Biopharma to combine its in vivo CAR platform with WestGene's targeted LNP delivery technology. The partnership will advance three programs: CRT-403 for autoimmune disease, CRT-401 for solid tumors, and a durable CD19 × BCMA RetroT program. The collaboration may be expanded by mutual agreement.BioSpaceCREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGeneCREATE Medicines announced a strategic collaboration with WestGene Biopharma to combine its in vivo CAR platform with WestGene's targeted LNP delivery technology. The partnership will advance three programs: a dual-target CD19 × BCMA CAR for autoimmune disease, a HER2 × TROP2 CAR for solid tumors, and a durable CD19 × BCMA RetroT program. The collaboration may be expanded by mutual agreement.Mirage NewsCREATE Medicines Boosts CAR Platform via Monash Deal 4 AugustCREATE Medicines has entered a strategic research collaboration with Monash University and its Monash Institute of Pharmaceutical Sciences (MIPS) to advance targeted in vivo CAR (Chimeric Antigen Receptor) therapy using Monash's lipid nanoparticle (LNP) technology. Under the agreement, CREATE receives a worldwide exclusive license to develop and commercialize CAR products arising from the collaboration, while MIPS will receive research funding and downstream milestone and royalty payments. The partnership aims to accelerate programmable medicines by combining CREATE's mRNA-LNP platform with Monash's novel LNP chemistries and next-generation targeting technologies for cell-specific delivery.Mirage NewsCREATE Medicines Boosts CAR Platform via Monash DealCREATE Medicines, a clinical-stage biotechnology company, announced a strategic research collaboration with Australia's Monash University and its Monash Institute of Pharmaceutical Sciences (MIPS) to advance targeted in vivo Chimeric Antigen Receptor (CAR) therapy development. Under the agreement, CREATE receives a worldwide exclusive license to all intellectual property arising from the collaboration along with rights to develop and commercialize CAR products, while MIPS will receive research funding plus downstream milestone and royalty payments. The partnership provides CREATE access to Monash's advanced lipid nanoparticle (LNP) technology, including proprietary binders and targeting innovations, to strengthen its in vivo immune programming platform for treating autoimmune diseases and cancer.AijournCREATE Medicines Expands Targeted In Vivo CAR Platform Through Strategic Research Collaboration and Exclusive License Agreement with Monash UniversityCREATE Medicines, a clinical-stage biotechnology company based in Cambridge, Massachusetts, announced a strategic research collaboration with Monash University and its Monash Institute of Pharmaceutical Sciences (MIPS) to advance targeted in vivo CAR therapy development. Under the agreement, CREATE receives a worldwide exclusive license to Monash's advanced lipid nanoparticle (LNP) technology and intellectual property, with rights to develop and commercialize CAR products, while MIPS will receive research funding plus downstream milestone and royalty payments. The partnership aims to overcome targeted delivery challenges in in vivo cell therapies by combining Monash's LNP expertise with CREATE's clinically validated mRNA platform.PR NewswireCREATE Medicines Expands Targeted In Vivo CAR Platform Through Strategic Research Collaboration and Exclusive License Agreement with Monash UniversityCREATE Medicines announced a strategic research collaboration and exclusive worldwide license agreement with Monash University and its Monash Institute of Pharmaceutical Sciences (MIPS) to access advanced lipid nanoparticle (LNP) technologies for targeted in vivo CAR therapy development. Under the agreement, CREATE gains exclusive rights to develop and commercialize CAR products directed to designated targets, while MIPS receives research funding and downstream milestone and royalty payments. The partnership aims to accelerate development of programmable medicines by combining Monash's LNP engineering expertise with CREATE's clinically validated mRNA-LNP platform for cell-type-specific delivery.Tech TimesIn Vivo CAR-T’s Liver Problem Now Has Targeted Answer: CREATE Acquires Monash’s 8-Fold LNP FixCREATE Medicines acquired an exclusive license to Monash University's antibody-capture system for lipid nanoparticles, which boosts mRNA delivery to target cells eightfold. The deal supports CREATE's first-in-human Phase 1/2 trial of CRT-402 for autoimmune diseases, approved in Australia. The collaboration aims to expand targeting for solid tumors.Labiotech.euEight in vivo CAR T biotechs to follow closelyEight in vivo CAR-T biotechs are profiled, including Umoja Biopharma, Vyriad, CPTx, Legend, Strand, Alaya.bio, AAVivo, and Create Medicines. Their lead candidates target CD19, BCMA, or other antigens, with some in clinical trials. Big pharma is acquiring these companies for billions.